Analyst Research

Report Title Price
Provider: Thomson Reuters Stock Report
Provider: Stock Traders Daily
Provider: Sadif Analytics Prime
Provider: ValuEngine, Inc.

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Allergan Inc confirms receipt of unsolicited proposal from Valeant Pharmaceuticals International Inc

Tuesday, 22 Apr 2014 11:00am EDT 

Allergan Inc:Confirms that it has received an unsolicited proposal from Valeant Pharmaceuticals International, Inc to acquire all of the outstanding shares of the company for a combination of 0.83 of Valeant common shares and $48.30 in cash per share of common stock of the company.Says its board , in consultation with its financial and legal advisors, will carefully review and consider the proposal and pursue the course of action that it believes is in the best interests of the company's stockholders.Goldman, Sachs & Co. and BofA Merrill Lynch are serving as financial advisors to the company.Latham & Watkins is serving as legal counsel to the company. 

Company Quote

0.65 +0.25%
28 Jul 2015